stay updated

Khondrion Appoints Jasper Levink as New CEO to Lead Next Phase of Growth

Khondrion, a Phase 3 clinical-stage biopharmaceutical company advancing therapies for primary mitochondrial diseases, today announced the appointment of Jasper Levink as its new Chief Executive Officer. He succeeds Prof. Jan Smeitink, the founder and CEO of Khondrion and a lifelong advocate formitochondrial medicine.

Khondrion and Medvisis Announce Exclusive Licensing Agreement to Commercialize Sonlicromanol for Primary Mitochondrial Diseases in Switzerland and Liechtenstein

Khondrion B.V. and Medvisis Switzerland AG today announced an exclusive licensing agreement for the registration and commercialization of sonlicromanol in Switzerland and Liechtenstein for the treatment of Primary Mitochondrial Diseases (PMD). Under the agreement, Medvisis receives exclusive rights to commercialize sonlicromanol in its territory. Financial terms were not disclosed.

Khondrion Secures EU Orphan Drug Designation for Lead Compound Sonlicromanol in Treatment of Inherited Mitochondrial Oxidative Phosphorylation Defects

NIJMEGEN, the Netherlands – August 4, 2025 – Khondrion announced that the European Commission has granted Orphan Drug Designation (ODD) to its lead investigational therapy, sonlicromanol, for the treatment of all inherited mitochondrial oxidative phosphorylation (OXPHOS) defects.

Khondrion Secures up to €5 Million Innovation Credit from Dutch Government plus Additional Funding from Current Investors to Advance Phase 3 Clinical Trial in m.3243A>G Primary Mitochondrial Disease

Khondrion, a clinical-stage biopharmaceutical companypioneering therapies for primary mitochondrial disease (PMD), today announced it has beenawarded an Innovation Credit of up to €5 million from the Netherlands Enterprise Agency, agovernment agency that supports entrepreneurs...

UMDF and Khondrion Announce The Mito Fund’s Investment in Khondrion to Support Development of One of the Most Advanced Drug Candidates for Primary Mitochondrial Disease

The United Mitochondrial Disease Foundation’s (UMDF) venture philanthropy arm, The Mito Fund, has invested in Khondrion...

Khondrion receives FDA clearance of IND application for pivotal Phase 3 clinical trial of sonlicromanol for the treatment of primary mitochondrial disease

52-week Phase 3 trial to investigate potential of novel, brain-penetrant redox-modulator with anti-inflammatory properties, in adult patients with...

Patient Perspective: A conversation with Elja van der Veer – Former IMP Chair

Can you explain a little about the work that International Mito Patients does? International Mito Patients (IMP) is a global network of 16 national...

Patient Perspective: A conversation with Elja van der Veer – Former IMP Chair

A coffee with the Scientific Advisory Board: Prof. Dr. Michelangelo Mancuso

How did you cross paths with Khondrion? I heard about Khondrion from International Mito-Patients, the global network of patient organisations, and...

Patient Perspective: A conversation with Sam’s mother

When did Sam first start experiencing symptoms and how long did it take for him to be diagnosed? Sam was first diagnosed with mitochondrial disease...

A coffee with the Scientific Advisory Board: Prof. Dr. Marni Falk

How did you cross paths with Khondrion? I have crossed paths with Jan Smeitink, Khondrion’s CEO and Founder, multiple times at various international...

Patient Perspective: A conversation with Paulien

When did you first start experiencing mitochondrial disease symptoms and how long did it take to get your diagnosis? I had a very happy and...